LivaNova (NASDAQ:LIVN) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note published on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $75.00 target price on the stock.

A number of other equities analysts have also recently issued reports on the company. Mizuho reduced their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 target price on the stock. Finally, StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 23rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Price Performance

Shares of LIVN opened at $50.53 on Tuesday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47. The stock has a market cap of $2.74 billion, a P/E ratio of 120.31 and a beta of 1.01. The stock’s 50-day moving average price is $49.05 and its two-hundred day moving average price is $49.97.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by insiders.

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently bought and sold shares of the company. Central Pacific Bank Trust Division acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $178,000. Captrust Financial Advisors acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $217,000. Sanctuary Advisors LLC acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $219,000. Edgestream Partners L.P. acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $244,000. Finally, GSA Capital Partners LLP acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $292,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.